Vaxcyte
PCVX · NASDAQ
$66.23+$2.55 (+4.00%)TodayMarket closed ·
Prev close $63.68
EPS: actual vs estimate
Beat the estimate in 4 of the last 8 quarters, by 12.5% on average
Next report: , after the market closes
- Quarter
- Q3 FY26
- EPS estimate
- -$2.06
Reported EPS
Estimated EPS
| Quarter | Estimate | Reported | Surprise |
|---|---|---|---|
| Q2 FY26 | -$2.10 | -$1.97 | +6.0% |
| Q1 FY26 | -$1.79 | -$2.30 | −28.7% |
| Q4 FY25 | -$1.55 | -$1.80 | −16.4% |
| Q3 FY25 | -$1.29 | -$1.56 | −20.5% |
| Q2 FY25 | -$1.19 | -$1.22 | −2.1% |
| Q1 FY25 | -$1.07 | -$1.04 | +2.7% |
| Q4 FY24 | -$1.16 | -$1.01 | +12.9% |
| Q3 FY24 | -$1.16 | -$0.83 | +28.3% |
Earnings calls
- Special Call - Vaxcyte, Inc.
- Bank of America Global Healthcare Conference 2026
- PCVX - Earnings call Q4 2025
- Jefferies London Healthcare Conference 2025
- Guggenheim Securities 2nd Annual Healthcare Innovation Conference
- Cantor Global Healthcare Conference 2025
- Goldman Sachs 46th Annual Global Healthcare Conference 2025
- BofA Securities 2025 Healthcare Conference
Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.